Advanced Search

 

Study ID Status Title Patient Level Data
NKV101983 Completed A Phase II Multicenter, Randomized, Double-Blind, Placebo-controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered as 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Moderately Emetogenic Chemotherapy
NKV102549 Completed A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea
NKV102551 Completed A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, administered in Combination with ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
NKV103444 Terminated An open label, repeat dose, randomized, two period crossover study to investigate the potential pharmacokinetic interactions between oral GW679769 and intravenous cyclophosphamide in cancer patients
NKV105091 Completed An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769] Study Listed on ClinicalStudyDataRequest.com
NKV105093 Completed An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of [GW679769] Study Listed on ClinicalStudyDataRequest.com
NKV105097 Completed An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin when Co-administered with Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects. Study Listed on ClinicalStudyDataRequest.com
NKV109990 Completed A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant in Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
NKV110483 Completed An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects Study Listed on ClinicalStudyDataRequest.com
NKV110721 Completed A Study of Single Dose Intravenous Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Oxaliplatin Induced Nausea and Vomiting.
NKV20001 Completed A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of the oral neurokinin-1 receptor antagonist, GW679769 When Administered at daily doses of 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy.
NN210005 Completed A Phase I, Multicenter, Randomized, Parallel, Double-Blinded Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Dosage Regimens of GW695634G Monotherapy Versus Placebo Over 10 days in ART-Naive HIV-1 Infected Adults.
NOS102512 Completed A Randomized, Single-Blind, Single-Attack, Placebo-Controlled, Adaptive Design Study to Assess the Safety and Efficacy of doses of 5-180 mg of the iNOS inhibitor GW274150 in the Treatment of Acute Migraine during the Mild Headache Phase
NOS103325 Completed A multicentre, two-part, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administered up to 120mg daily for 12 Weeks in the prophylactic treatment of migraine.
NUC 30956 Completed AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (presumed pre-core mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.
O7921353 Completed A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males
OEF0701 Completed A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis
OFA110867 Completed Clinical phase I/IIA study of subcutaneously administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate
OHB20001 Completed A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects with Major Depressive Disorder for a Treatment period of Eight Weeks
OHB20002 Completed A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period.
OHB20003 Completed A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (40-60mg) Versus Placebo in Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period.
OLA103920 Completed First time in human, single dose and repeat dose study to assess the safety, tolerability and pharmacokinetics of GSK615915
OM5 program (Reliant) Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Omacor Therapy in Hypertriglyceridemic Subjects Treated with Antara, followed by an 8-week extension Study Listed on ClinicalStudyDataRequest.com
OM6 program (Reliant) Completed A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Omacor and Simvastatin Therapy in Hypertriglyceridemic Subjects Study Listed on ClinicalStudyDataRequest.com
OM8 Afib Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.